Product Information
DEPAKOTE ER 250 MG TABLET is a brand product labeled by AbbVie Inc., priced at $3.6870 per EA under NDC 00074740113. Its NADAC has been published 200 times since Oct 12, 2022.
FDA first approved this application on Aug 4, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Divalproex Sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/1
Manufacturer
AbbVie Inc.NDC
00074740113
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DIVALPROEX SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021168FDA Approved
8/4/2000
TE Code
AB
On Market Since
8/4/2000
Pharmacological Classes
Price Statistics
The NADAC for DEPAKOTE ER 250 MG TABLET has been published 200 times since Oct 12, 2022, and over the history we have for it it has risen 21.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.6870 per EA |
|---|---|
| All-time high | $3.6874 (Sep 16, 2026) |
| All-time low | $3.0405 (Oct 12, 2022) |
| 52-week high | $3.6874 |
| 52-week low | $3.5116 |
| Median price | $3.3531 |
| Average price | $3.4096 |
| Largest weekly change | +5.1% (Jan 18, 2023) |
| Weeks tracked | 200 |
| Tracking since | Oct 12, 2022 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Divalproex Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEPAKOTE ER 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DEPAKOTE ER 250 MG TABLET, manufactured by AbbVie Inc., is $3.6870 per EA (NDC 00074740113), effective Sep 30, 2026.
How has the price of DEPAKOTE ER 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for DEPAKOTE ER 250 MG TABLET has risen 21.3%. It has been tracked across 200 weekly CMS publications since Oct 12, 2022.
What are the highest and lowest recorded NADAC prices for DEPAKOTE ER 250 MG TABLET?
Since Oct 12, 2022, the NADAC for DEPAKOTE ER 250 MG TABLET has ranged from a low of $3.0405 (Oct 12, 2022) to a high of $3.6874 (Sep 16, 2026), with a median of $3.3531 per EA.
Are there cheaper alternatives to DEPAKOTE ER 250 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DIVALPROEX SOD DR 250 MG TAB, is $0.0833 per EA — about 98% below DEPAKOTE ER 250 MG TABLET.
Who manufactures DEPAKOTE ER 250 MG TABLET?
DEPAKOTE ER 250 MG TABLET (NDC 00074740113) is labeled by AbbVie Inc., and CMS classifies it as a brand product.